Institution / University and research network
Founded in 1827, the University of Toronto became the institutional centre of the research, clinical testing, production agreements, and archival memory associated with the development of insulin.
Insulin was not produced by an isolated flash of genius. It emerged through university laboratories, animal experiments, biochemical collaboration, hospital patients, manufacturing capacity, patent decisions, and the coordination of a research team.
Insulin as institutional work
The university supplied laboratory space, personnel, professional authority, and relationships with hospitals and manufacturers. Those resources turned a promising pancreatic extract into a treatment that could be tested and distributed.
Frederick Banting brought an experimental proposal to physiology professor J. J. R. Macleod. Macleod provided laboratory support and Charles Best assisted with the 1921 experiments; biochemist James Collip later helped refine the extract.
The work moved from laboratory animals to clinical use through Toronto General Hospital. In January 1922, Leonard Thompson received the first clinical injections, with a purified preparation producing the decisive response.
University structures helped coordinate patents, quality control, and production partnerships. Connaught Laboratories and commercial manufacturers became essential to transforming small experimental batches into a reproducible therapy.
Credit, ownership, access
The 1923 Nobel Prize went to Banting and Macleod, who shared their awards with Best and Collip. Disputes over credit helped produce a simplified public story centred on Banting and Best, sometimes obscuring biochemical, clinical, technical, and manufacturing labour.
The research team assigned insulin patent rights to the university in an effort to supervise quality and availability. Yet institutional stewardship did not settle the long history of insulin access, pricing, industrial ownership, and unequal treatment.
The university itself grew from a settler-colonial endowment and inherited lands appropriated from Indigenous peoples. Its medical achievements belong within that broader history of accumulated institutional resources and uneven public benefit.
From dose to daily life
Insulin did not cure diabetes. Patients needed reliable supplies, repeated injections, monitoring, dietary knowledge, clinical follow-up, and the means to manage treatment outside hospital. The discovery therefore shifted work into homes as well as factories and clinics.
That continuing dependency makes production history clinically important. Purity, concentration, storage, delivery devices, and price all shaped whether laboratory success translated into safe everyday treatment.
Across the collection
Follow ancient descriptions, diet, pancreatic research, treatment, chronic care, and access.
Place laboratory development and clinical use on the site's chronological spine.
Compare insulin's early testing with later systems of therapeutic evidence and regulation.